Delving into the Latest Updates on Technische Universität Braunschweig with Synapse

概览

疾病领域	数量

免疫系统疾病	4
神经系统疾病	2
肿瘤	2
感染	1

排名前五的药物类型	数量

Fc融合蛋白	2
CAR-T	2
小分子化药	1

排名前五的靶点	数量

NMDA receptor(谷氨酸[NMDA]受体复合体)	2
CD39L3(ectonucleoside triphosphate diphosphohydrolase 3)	1
DGCR2(DiGeorge syndrome critical region gene 2)	1

关联

5

项与 Technische Universität Braunschweig 相关的药物

PF-1140

靶点-

作用机制-

在研机构

Technische Universität Braunschweig [+2]

原研机构

Meiji Seika Pharma Co., Ltd.

在研适应症

真菌病

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

GluN1-GluN2B-Fc (Yumab)

靶点

NMDA receptor

作用机制

NMDA receptor拮抗剂

在研机构

Technische Universität Braunschweig [+1]

原研机构

Yumab Gmbh [+1]

在研适应症

抗-N-甲基-D-天冬氨酸受体脑炎

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

GluN1-GluN2A-Fc (YUMAB)

靶点

NMDA receptor

作用机制

NMDA receptor拮抗剂

在研机构

Technische Universität Braunschweig [+1]

原研机构

Yumab Gmbh [+1]

在研适应症

抗-N-甲基-D-天冬氨酸受体脑炎

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

1

项与 Technische Universität Braunschweig 相关的临床试验

DRKS00006069

/ CompletedN/A

Consequences of Child Neglect and Maltreatment under Different Intervention Conditions (TP TREAT-Part) - GROW&TREAT

开始日期2014-04-07

申办/合作机构

Technische Universität Braunschweig

100 项与 Technische Universität Braunschweig 相关的临床结果

登录后查看更多信息

0 项与 Technische Universität Braunschweig 相关的专利（医药）

登录后查看更多信息

10,002

项与 Technische Universität Braunschweig 相关的文献（医药）

2025-08-01·JOURNAL OF HOSPITAL INFECTION

Defining water safety in healthcare premises

Review

作者: Meda, M ; Weinbren, M ; Hopman, J ; Sunder, W ; Fucini, G

The term 'water safety' originated in a time when the risk emanating from the wastewater system was not appreciated. Water and wastewater systems are uniquely intertwined. Each may impact on the other to have an adverse effect on patient safety. Risk to patient safety may be introduced at any point from mains water entering a site right through to wastewater exiting the site to join the municipal sewers. These risks begin at inception of a new-build project, through every stage of the life cycle of a building, through to decommissioning. The term 'water safety' is outdated as it does not consider the different structural areas of the water/wastewater system which may give rise to unique risks. This, in turn, hinders the development of expertise, necessary training, guidelines, research, etc. specific to the area. It is therefore proposed that water/wastewater systems should be divided into three zones: (A) main body of the water system; (B) periphery of the water/wastewater system; and (C) main body of in-premise wastewater system. It is recommended that the term 'water safety' should be used to refer to the main body of the in-premise water system. It is recommended that the term 'clinically integrated water/wastewater safety' should be used to refer to the periphery of the water/wastewater system. It is recommended that the term 'wastewater safety' should be used to refer to the main body of the wastewater system. It is recommended that both the periphery of the water/wastewater system and the main body of the wastewater system should be recognized in their own right, necessitating development of specific training and expertise in each area. The water safety group should accordingly change their title to the 'water/wastewater safety group'. The range of stakeholders and knowledge base required to ensure water/wastewater safety needs to be expanded, delineated and recognized. Depending on the nature of the stakeholder, this could require improved exchange of information, development of training and expertise, etc.

2025-06-01·JOURNAL OF MATERIALS ENGINEERING AND PERFORMANCE

Investigation of Polyamide 12 Powder Cooling Process under Natural Convection via Porous Medium, Non-porous Medium, and Experimental Approaches

作者: Tavakoli, Mohammad Reza ; Mojaddarasil, Mohammad

Thermal issues in the selective laser sintering process have been one of the major concerns of researchers so far due to their vital importance to the mech. properties of the final manufactured products.This paper is a numerical and exptl. study in which the cool-down process of the PA12 powder is assessed using two different methods: a porous medium and a non-porous medium.Then, by comparing the numerical results with the exptl. ones, the study aims to suggest the best method for simulating the heat transfer in PA12 powder.Moreover, after approving the method of simulation, using this method, the powder cool-down process under natural convection from around the construction temperature (170°C) to a temperature close to the ambient temperature (27°C) is simulated by considering both the powder and the ambient gas for four different gases (air, nitrogen, argon, and helium) aiming to assess the heat transfer coefficient for each of the scenarios.The paper's main findings include: first, the non-porous medium point of view outperforms the porous medium; second, four different formulas are proposed for the natural convective heat transfer coefficient of PA12 and each of the studied gases.

2025-02-01·BIOCHEMICAL PHARMACOLOGY

Runcaciguat activates soluble guanylyl cyclase via the histidine essential for heme binding and nitric oxide activation

Article

作者: Rühle, Anne ; Elgert, Christin ; Mathar, Ilka ; Behrends, Sönke ; Wittrien, Theresa ; Sandner, Peter

Soluble guanylyl cyclase (sGC) is a well-established pharmacological target for the treatment of acute angina pectoris, pulmonary hypertension and heart failure. Histidine 105 in the heme binding pocket of sGC is a crucial residue for heme binding and natural enzyme activation by NO. It was assumed that the heme-free sGC mutants α₁/β₁H105F and α₁/β₁H105A were valuable research tools for studying NO independent sGC activators. These mutants have been used in drug screening and animal models. We confirm that the first generation of sGC activators cinaciguat and BAY 60-2770 activate the α₁/β₁H105F and α₁/β₁H105A mutants. In contrast, we show that the second generation sGC activators runcaciguat and BAY 543 only activate heme-free sGC when the β₁H105 residue is present. By testing runcaciguat in β₁ H105F knock-in mice, we confirm this histidine-dependency in vivo. We propose a novel classification of sGC activators, distinguishing between the histidine-dependent activators runcaciguat and BAY 543 and the histidine-independent activators cinaciguat, BAY 60-2770 and BI703704. The histidine-dependency of some of the sGC activators provides a compelling rationale for a re-evaluation of previous research and drug development programs based on sGC histidine mutants. Whether the classification of sGC activators based on the activation mechanism also makes a therapeutic difference needs to be clarified in the future.

1

项与 Technische Universität Braunschweig 相关的新闻（医药）

2022-06-15

·BioSpace

Ymmunobio Signs Collaboration Agreement with YUMAB

RIEHEN, SWITZERLAND, June 14, 2022 ─ Ymmunobio AG, a preclinical stage biotech company specializing in the development of CEACAM (carcinoembryonic antigen-related cell adhesion molecules) antibodies as anti-cancer treatments, today announced that it has signed a collaboration agreement with YUMAB GmbH, a privately-held German biotechnology company. YUMAB provides technologies and contract research for the development of fully human antibodies for all therapeutic fields. Within the scope of the collaboration, Ymmunobio AG will complement its antibody development by utilizing YUMAB’s expertise and platform for optimizing its antibodies. “We look forward to our collaboration being a productive complement to our capabilities,” said Dr. Katrin Rupalla, CEO, Ymmunobio AG. “Ymmunobio shares a commitment with YUMAB to accelerate drug development through antibody optimization.” “We’re excited by the prospect of working with Ymmunobio to facilitate new pathways to antibody development,” said Dr. Thomas Schirrmann, YUMAB founder and CEO. “Ymmunobio shares our vision to accelerate drug discovery and ultimately improve patient outcomes.” Ymmunobio is developing a proprietary class of CEACAM1 immune agonistic antibodies in order to employ the immune system to fight cancer. Financial conditions of the agreement were not disclosed. ABOUT YMMUNOBIO Ymmunobio AG, a preclinical stage oncology biotech company, was founded by Dr. Katrin Rupalla and is committed to developing a proprietary class of CEACAM antibodies to increase the efficiency of the adaptive and innate immune system to fight cancer. Ymmunobio’s research targets defined CEACAM receptor isoforms that play a major role in the immune response and cancer cell evolution. The company’s proprietary platform is based on the leading research of Dr. Bernhard B. Singer, University Essen/Duisburg, Germany. ABOUT YUMAB YUMAB GmbH, a leading provider of contract research, technologies, and R&D services for the development of fully human, therapeutic antibodies, was founded in 2012 by scientists of the University of Braunschweig. A global player in human monoclonal antibody development, YUMAB is focused on the use of fully human antibodies for immunotherapies. For more information, please visit . Contact: Dr. Katrin Rupalla, info@ymmuno.bio

合作抗体

100 项与 Technische Universität Braunschweig 相关的药物交易

登录后查看更多信息

100 项与 Technische Universität Braunschweig 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2025年08月30日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

2

3

临床前

其他

2

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

GluN1-GluN2A-Fc (YUMAB) ( NMDA receptor )	抗-N-甲基-D-天冬氨酸受体脑炎更多	临床前
PF-1140	真菌病更多	临床前
GluN1-GluN2B-Fc (Yumab) ( NMDA receptor )	抗-N-甲基-D-天冬氨酸受体脑炎更多	临床前
WO2024156716 ( CD39L3 )专利挖掘	免疫系统疾病更多	药物发现
WO2024175805 ( DGCR2 )专利挖掘	免疫系统疾病更多	药物发现